Prediction of Distant Recurrence by EndoPredict in Patients with Estrogen Receptor Positive, HER2 Negative Breast Cancer who Received Adjuvant Endocrine Therapy plus …

Conclusions• A total of 3746 women with ER-positive, HER2-negative disease were included in this analysis.• 2630 patients received 5 years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET+ C (GEICAM 2003-02/9906).• The primary objective was to evaluate the 10-year DRFI rates as a continuous function of EPclin separately for patients in ET+ C and ET.• Secondary objectives included assessing prognostic ability of EPclin between ET+ C and ET for specific follow-up periods (years 0-10, 0-5 and 5-10).